Concert Pharmaceuticals announced top-line results this week for CTP-543. The single and multiple ascending dose study was well-tolerated across all dose groups. The company is planning on testing four doses (4, 8, 12, and 16 mg BID) in the phase 2 clinical trial scheduled to begin early 2017. The phase 2 clinical trial will enroll around 100 patients with moderate to severe alopecia areata, with six month readout by the end of 2017. Thank you for reading.
No comments:
Post a Comment